Apremilast (CAS 608141-41-9)
QUICK LINKS
Apremilast exhibits greater potency in inhibiting PDE4 compared to other PDE families responsible for hydrolyzing cAMP or cGMP. Its anti-inflammatory effects are widespread across various cell types, encompassing the inhibition of TNF-α, IL-12, and IL-23 production, as well as suppressing NK cell and keratinocyte responses. Apremilast effectively hampers the zymosan-induced production of IL-8 in PMNs, with an IC50 value of 94 nM. Additionally, it inhibits PMN CD18 and CD11b expression induced by fMLF, with IC50 values of 390 nM and 74 nM, respectively. Moreover, Apremilast curtails the adhesion of PMNs to HUVECs triggered by fMLF, with an IC50 value of 150 nM. Notably, Apremilast′s suppression of keratinocyte TNF-α production does not impact keratinocyte cell viability, as evidenced by intracellular ATP levels remaining unaffected.
Apremilast (CAS 608141-41-9) References
- Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. | Abdulrahim, H., et al. 2015. Expert Opin Pharmacother. 16: 1099-108. PMID: 25864487
- Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. | Gisondi, P. and Girolomoni, G. 2016. Drug Des Devel Ther. 10: 1763-70. PMID: 27307707
- Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis. | . 2016. Prescrire Int. 25: 149-51. PMID: 27486641
- Apremilast for the management of moderate to severe plaque psoriasis. | Vangipuram, R. and Alikhan, A. 2017. Expert Rev Clin Pharmacol. 10: 349-360. PMID: 28276777
- Analytical Methods for Determination of Apremilast from Bulk, Dosage Form and Biological Fluids: A Critical Review. | Kulkarni, P. and Deshpande, A. 2021. Crit Rev Anal Chem. 51: 258-267. PMID: 32024370
- Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis via PI3K/AKT/FoxO1 Signaling Pathway. | Chen, Y., et al. 2020. Front Immunol. 11: 581673. PMID: 33281814
- Apremilast prevents IL‑17‑induced cellular senescence in ATDC5 chondrocytes mediated by SIRT1. | Wang, B., et al. 2021. Int J Mol Med. 47: PMID: 33448323
- Apremilast ameliorates IL-1α-induced dysfunction in epidermal stem cells. | Jia, Y., et al. 2021. Aging (Albany NY). 13: 19293-19305. PMID: 34375302
- Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis. | Ivanic, MG., et al. 2021. J Drugs Dermatol. 20: 837-843. PMID: 34397197
- Apremilast effectively inhibits TNFα-induced vascular inflammation in human endothelial cells. | Otto, M., et al. 2022. J Eur Acad Dermatol Venereol. 36: 237-246. PMID: 34699634
- Apremilast retention rate in clinical practice: observations from an Italian multi-center study. | Ariani, A., et al. 2022. Clin Rheumatol. 41: 3219-3225. PMID: 35796847
- Evolving utility of apremilast in dermatological disorders for off-label indications. | Mehta, H., et al. 2022. Clin Exp Dermatol. 47: 2136-2149. PMID: 35974705
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. | Strober, B., et al. 2023. J Am Acad Dermatol. 88: 40-51. PMID: 36115523
- Apremilast for the Treatment of Concomitant Subacute Cutaneous Lupus Erythematosus and Psoriasis. | Tsiogka, A., et al. 2022. Skinmed. 20: 391-392. PMID: 36314710
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Apremilast, 5 mg | sc-480062 | 5 mg | $444.00 |